Diamonds in the Rough
Cross-referencing fundamental value against technical exhaustion to isolate beaten-down ARKG constituents that screen cheap and oversold. The bottom-right quadrant — high earnings yield, low RSI — is the prime hunting ground, especially where money flow (MFI) shows quiet accumulation despite the falling price.
Educational screen, not investment advice. “Diamond” classification is a mechanical valuation-vs-RSI split around the cohort median earnings yield and an RSI of 50.
Alpha Quadrant — Valuation × Technical Exhaustion
X = earnings yield (cheaper right) · Y = RSI 14 (more oversold lower) · bubble = market cap · color = money flow.
Diamond Candidates
Ranked by a composite of earnings yield, ROIC, oversold RSI, recent weakness, and improving money flow.
| # | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co. | 42.8 | 3.03% | 0.70 | 42 | -8.08% | 27 | safe |
| 2 | VCYT | Veracyte, Inc. | 40.0 | 1.93% | 0.13 | 39 | -8.89% | 54 | safe |
| 3 | BEAM | Beam Therapeutics Inc. Common Stock | 30.0 | -16.27% | -0.30 | 34 | -11.52% | 30 | safe |
| 4 | IONS | Ionis Pharmaceuticals, Inc. Common Stock | 29.0 | -3.53% | -0.20 | 30 | -8.96% | 17 | grey |
| 5 | BFLY | Butterfly Network, Inc. | 25.0 | -4.48% | -0.42 | 42 | -21.17% | 50 | safe |
| 6 | ABSI | Absci Corporation Common Stock | 24.3 | -9.25% | -0.81 | 41 | -15.55% | 45 | safe |
| 7 | ILMN | Illumina Inc | 24.2 | 2.51% | 0.33 | 51 | +7.32% | 54 | safe |
| 8 | QSI | Quantum-Si Incorporated Class A Common Stock | 24.2 | -84.65% | -0.71 | 41 | -15.20% | 39 | distress |
| 9 | ALMR | Alamar Biosciences, Inc. Common Stock | 23.4 | -- | -- | 42 | -15.77% | 41 | -- |
| 10 | CERS | Cerus Corp | 17.4 | -0.58% | -0.04 | 44 | -6.59% | 33 | distress |
| 11 | NRIX | Nurix Therapeutics, Inc. Common stock | 16.8 | -11.26% | -0.53 | 48 | -5.20% | 55 | safe |
| 12 | PRME | Prime Medicine, Inc. Common Stock | 15.1 | -40.05% | -1.42 | 43 | -1.55% | 48 | distress |
| 13 | NTLA | Intellia Therapeutics, Inc | 14.2 | -28.66% | -1.00 | 43 | -1.94% | 34 | distress |
| 14 | CRSP | CRISPR Therapeutics AG | 13.4 | -12.55% | -0.34 | 44 | -2.43% | 26 | safe |
| 15 | PACB | Pacific Biosciences of California, Inc. | 10.7 | -56.09% | -1.70 | 51 | +19.47% | 59 | distress |
Short-Squeeze Watch
Constituents with the highest composite squeeze score — heavy short interest meeting price support.
| # | |||||||
|---|---|---|---|---|---|---|---|
| 1 | WGS | GeneDx Holdings Corp. Class A Common Stock | 86.7 | 31.95% | 12.43 | +8.67% | critical |
| 2 | RXRX | Recursion Pharmaceuticals, Inc. Class A Common Stock | 83.4 | 41.27% | 10.60 | +3.02% | critical |
| 3 | PRME | Prime Medicine, Inc. Common Stock | 82.9 | 36.37% | 13.13 | -1.55% | critical |
| 4 | SDGR | Schrodinger, Inc. Common Stock | 81.9 | 21.16% | 11.76 | +11.80% | critical |
| 5 | BEAM | Beam Therapeutics Inc. Common Stock | 79.7 | 32.36% | 14.84 | -11.52% | critical |
| 6 | ABSI | Absci Corporation Common Stock | 78.4 | 30.82% | 12.53 | -15.55% | critical |
| 7 | NTLA | Intellia Therapeutics, Inc | 76.8 | 38.29% | 12.89 | -1.94% | critical |
| 8 | CRSP | CRISPR Therapeutics AG | 75.2 | 22.69% | 10.73 | -2.43% | critical |
| 9 | TWST | Twist Bioscience Corporation Common Stock | 69.6 | 22.51% | 6.91 | +6.76% | high |
| 10 | ARCT | Arcturus Therapeutics Holdings Inc. Common Stock | 65.7 | 26.77% | 3.06 | +101.18% | high |
| 11 | NRIX | Nurix Therapeutics, Inc. Common stock | 65.3 | 18.29% | 15.94 | -5.20% | high |
| 12 | PACB | Pacific Biosciences of California, Inc. | 65.3 | 19.87% | 6.75 | +19.47% | high |
Market cap, valuation, and short-interest metrics are joined to the latest ARKG holdings snapshot; each ticker links to its full quote and analysis page.